Hyun Jun Park1, Jong Kwan Park2, Kwangsung Park3, Kweonsik Min4, Nam Cheol Park5. 1. Department of Urology, Pusan National University School of Medicine, Buan, Korea. 2. Department of Urology, Chonbuk National University Medical School, Jeonju, Korea. 3. Department of Urology, Chonnam National University Medical School, Gwangju, Korea. 4. Department of Urology, Inje University College of Medicine, Busan, Korea. 5. Department of Urology, Pusan National University School of Medicine, Buan, Korea. Electronic address: pnc@pusan.ac.kr.
Abstract
INTRODUCTION:Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction (ED). AIM: To evaluate the efficacy of udenafil in treating ED for up to 12 hours after dosing. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group, fixed dose design, multicenter study. Following a 4-week nondrug baseline period, 104 men with ED of broad etiology and severity were randomized to one of two treatment groups: udenafil 100 mg or placebo. Participants were requested to attempt sexual intercourse at 12 hours after udenafil or placebo dosing during a 4-week treatment period. MAIN OUTCOME MEASURES: The primary efficacy variable was the response of patients to question 3 of the Sexual Encounter Profile (SEP Q3). The secondary efficacy measures were the response of patients to question 2 of the Sexual Encounter Profile (SEP Q2). Additional secondary efficacy measures included changes from baseline in the erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire. RESULTS: Of the 104 patients, 103 (50 in the udenafil group, 53 in the placebo group) completed the study. Udenafil significantly enhanced the rate of maintenance of erection (SEP Q3; placebo, 28.3% vs. udenafil, 54.7%; P < 0.0001). Significant change from baseline in the IIEF-EF domain was observed in the udenafil group (placebo, -0.58 ± 0.67; udenafil, 4.40 ± 0.84; P < 0.0001). For SEP Q2, there was no difference from baseline and no difference between the two groups. The overall adverse events rate was 11.3%. Most adverse events were mild or moderate in severity, and no serious adverse events were reported during the study and the follow-up period. CONCLUSIONS:Udenafil at 100 mg was effective for relieving ED for up to 12 hours after dosing. This duration of effectiveness could allow for flexibility and spontaneity in the sexual lives of patients.
RCT Entities:
INTRODUCTION:Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction (ED). AIM: To evaluate the efficacy of udenafil in treating ED for up to 12 hours after dosing. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group, fixed dose design, multicenter study. Following a 4-week nondrug baseline period, 104 men with ED of broad etiology and severity were randomized to one of two treatment groups: udenafil 100 mg or placebo. Participants were requested to attempt sexual intercourse at 12 hours after udenafil or placebo dosing during a 4-week treatment period. MAIN OUTCOME MEASURES: The primary efficacy variable was the response of patients to question 3 of the Sexual Encounter Profile (SEP Q3). The secondary efficacy measures were the response of patients to question 2 of the Sexual Encounter Profile (SEP Q2). Additional secondary efficacy measures included changes from baseline in the erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire. RESULTS: Of the 104 patients, 103 (50 in the udenafil group, 53 in the placebo group) completed the study. Udenafil significantly enhanced the rate of maintenance of erection (SEP Q3; placebo, 28.3% vs. udenafil, 54.7%; P < 0.0001). Significant change from baseline in the IIEF-EF domain was observed in the udenafil group (placebo, -0.58 ± 0.67; udenafil, 4.40 ± 0.84; P < 0.0001). For SEP Q2, there was no difference from baseline and no difference between the two groups. The overall adverse events rate was 11.3%. Most adverse events were mild or moderate in severity, and no serious adverse events were reported during the study and the follow-up period. CONCLUSIONS:Udenafil at 100 mg was effective for relieving ED for up to 12 hours after dosing. This duration of effectiveness could allow for flexibility and spontaneity in the sexual lives of patients.
Authors: George T Kedia; Stefan Ückert; Dimitrios Tsikas; Armin J Becker; Markus A Kuczyk; Andreas Bannowsky Journal: J Clin Med Date: 2020-09-16 Impact factor: 4.241
Authors: Ji Kan Ryu; Kang Su Cho; Su Jin Kim; Kyung Jin Oh; Sung Chul Kam; Kyung Keun Seo; Hong Seok Shin; Soo Woong Kim Journal: World J Mens Health Date: 2013-08-31 Impact factor: 5.400